ClinicalTrials.gg
CompletedNCT02996110FRACTION-RCCUpdated Dec 19, 2022Results posted

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

A Phase 2 interventional study of Nivolumab and Ipilimumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-19.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with
  • of at least 3 months
  • Performance Status (KPS) must be =>70%

Exclusion criteria

Exclusion Criteria:

  • Patients/subjects with suspected or known central nervous system unless adequately treated
  • Patients/subjects with disease
  • Patients/subjects who need daily oxygen therapy

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Active comparator
    Nivolumab + Ipilimumab

    Nivolumab + Ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab + Relatlimab

    Nivolumab + Relatlimab

    Biological: Nivolumab · Biological: Relatlimab

  • Experimental
    Nivolumab + BMS-986205

    Nivolumab + BMS-986205

    Biological: Nivolumab · Drug: BMS-986205

  • Experimental
    Nivolumab + BMS-813160

    Nivolumab + BMS-813160 (CCR2/5 dual antagonist)

    Biological: Nivolumab · Drug: BMS-813160

Interventions

  • BiologicalNivolumab

    Specified Dose on Specified Days

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified Dose on Specified Days

    Also known as: BMS-734016, Yervoy

  • BiologicalRelatlimab

    Specified Dose on Specified Days

    Also known as: BMS-986016

  • Specified Dose on Specified Days

  • Specified Dose on Specified Days

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Investigator

    ORR is percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. For participants who received re-treatment or were re-randomized, the re-treatment and re-randomized therapies were considered subsequent anticancer therapy. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.

    Time frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks)

  2. Median Duration of Response (DOR) Per Investigator

    Duration of Response is defined as the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause (death occurring after re-treatment or randomization to new combination treatment was not considered), whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method

    Time frame: From first dose to the date of first documented disease progression or death due to any cause (assessed from an average of 22 weeks up to approximately 247 weeks)

  3. Progression Free Survival Rate (PFSR) at 24 Weeks.

    The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula

    Time frame: 24 weeks after first treatment dose.

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization

    Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)

  3. Number of Participants With Adverse Events (AEs) Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)

  4. Number of Participants Who Died

    Death is defined as the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.

    Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)

  5. Number of Participants With Abnormal Thyroid Test Results - Track 1

    The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.

    Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)

  6. Number of Participants With Abnormal Thyroid Test Results - Track 2

    The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)

  7. Number of Participants With Abnormal Hepatic Test Results - Track 1

    The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)

  8. Number of Participants With Abnormal Hepatic Test Results - Track 2

    The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)

07

Results

Posted Dec 19, 2022

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Started6556261718
Completed6555251716
Not completed01102
Withdrew: Other reasons01001
Withdrew: Participant withdrew consent00101
Track 1
Participant flow — Track 1
MilestoneArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Started3030000
Re-randomized to track 256000
Completed78000
Not completed2322000
Withdrew: Disease progression1517000
Withdrew: Adverse event unrelated to study drug11000
Withdrew: Study drug toxicity53000
Withdrew: Participant requested to discontinue study treatment10000
Withdrew: Administrative reason by sponsor01000
Withdrew: Participant no longer met study criteria10000
Track 2
Participant flow — Track 2
MilestoneArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Started4632312122
No pre-randomization3525251716
Re-randomized from track 1 nivolumab + relatlimab20211
Re-randomized from track 1 nivolumab + ipilimumab03110
Re-randomized from track 2 nivolumab + relatlimab70201
Re-randomized from track 2 nivolumab + bms98620522012
Previously un-treated but re-randomized00010
Re-randomized from track 2 nivolumab + ipilimumab02102
Completed43111
Not completed4229302021
Withdrew: Disease progression3326191615
Withdrew: Adverse event unrelated to study drug40011
Withdrew: Death00101
Withdrew: Study drug toxicity41410
Withdrew: Participant requested to discontinue study treatment00212
Withdrew: Participant withdrew consent12311
Withdrew: Other reasons00101

Outcome measures

PrimaryObjective Response Rate (ORR) Per Investigator

ORR is percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. For participants who received re-treatment or were re-randomized, the re-treatment and re-randomized therapies were considered subsequent anticancer therapy. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.

Time frame:
From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR) Per Investigator
Percent of participantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 120 (7.7 to 38.6)30 (14.7 to 49.4)———
Track 217.4 (7.8 to 31.4)3.1 (0.1 to 16.2)3.2 (0.1 to 16.7)9.5 (1.2 to 30.4)0.0 (0.0 to 15.4)
PrimaryMedian Duration of Response (DOR) Per Investigator

Duration of Response is defined as the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause (death occurring after re-treatment or randomization to new combination treatment was not considered), whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method

Time frame:
From first dose to the date of first documented disease progression or death due to any cause (assessed from an average of 22 weeks up to approximately 247 weeks)
Reported as:
Median · Weeks
Median Duration of Response (DOR) Per Investigator
WeeksArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 1NA (33.4 to 139.9)32.57 (0.1 to 52.6)———
Track 268.00 (0.1 to 117.6)99.4 (99.4 to 99.4)NA (NA to NA)NA (NA to NA)—
PrimaryProgression Free Survival Rate (PFSR) at 24 Weeks.

The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula

Time frame:
24 weeks after first treatment dose.
Reported as:
Number · Proportion of participants
Progression Free Survival Rate (PFSR) at 24 Weeks.
Proportion of participantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 10.491 (0.294 to 0.661)0.429 (0.246 to 0.600)———
Track 20.432 (0.277 to 0.577)0.194 (0.079 to 0.346)0.278 (0.118 to 0.464)0.468 (0.237 to 0.670)NA (NA to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 12930———
Track 24532311921
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization

Time frame:
From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 11715———
Track 2281616915
SecondaryNumber of Participants With Adverse Events (AEs) Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) Leading to Discontinuation
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 177———
Track 2103624
SecondaryNumber of Participants Who Died

Death is defined as the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.

Time frame:
From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Reported as:
Number · Participants
Number of Participants Who Died
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
Track 11215———
Track 22717131013
SecondaryNumber of Participants With Abnormal Thyroid Test Results - Track 1

The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.

Time frame:
From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Thyroid Test Results - Track 1
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
TSH > ULN88000
TSH > ULN WITH TSH <= ULN AT BASELINE58000
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN33000
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN32000
TSH > ULN WITH FT3/FT4 TEST MISSING23000
TSH < LLN105000
TSH <LLN WITH TSH >= LLN AT BASELINE95000
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN30000
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN21000
TSH < LLN WITH FT3/FT4 TEST MISSING54000
SecondaryNumber of Participants With Abnormal Thyroid Test Results - Track 2

The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Thyroid Test Results - Track 2
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
TSH > ULN1414634
TSH > ULN WITH TSH <= ULN AT BASELINE86322
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN53110
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN54323
TSH > ULN WITH FT3/FT4 TEST MISSING47201
TSH < LLN45221
TSH <LLN WITH TSH >= LLN AT BASELINE24121
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN10110
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN03000
TSH < LLN WITH FT3/FT4 TEST MISSING32111
SecondaryNumber of Participants With Abnormal Hepatic Test Results - Track 1

The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hepatic Test Results - Track 1
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
ALT OR AST > 3XULN24000
ALT OR AST> 5XULN12000
ALT OR AST> 10XULN000000
ALT OR AST > 20XULN00000
TOTAL BILIRUBIN > 2XULN00000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY00000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS00000
SecondaryNumber of Participants With Abnormal Hepatic Test Results - Track 2

The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hepatic Test Results - Track 2
ParticipantsArm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mg
ALT OR AST > 3XULN31100
ALT OR AST> 5XULN20100
ALT OR AST> 10XULN00000
ALT OR AST > 20XULN00000
TOTAL BILIRUBIN > 2XULN20000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY00000
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS00000

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 250 weeks). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Track 1: Nivolumab Plus Ipilimumab (BMS-734016)12/30 (40%)17/30 (56.7%)28/30 (93.3%)
Track 1: Nivolumab Plus Relatlimab (BMS-986016)15/31 (48.4%)15/30 (50%)29/30 (96.7%)
Track 2: Nivolumab Plus Ipilimumab (BMS-734016)27/46 (58.7%)28/46 (60.9%)42/46 (91.3%)
Track 2: Nivolumab Plus Relatlimab (BMS-986016)17/32 (53.1%)16/32 (50%)31/32 (96.9%)
Track 2: Nivolumab Plus BMS-98620513/32 (40.6%)16/31 (51.6%)29/31 (93.5%)
Track 2: Nivolumab Plus BMS-813160 150 mg10/21 (47.6%)9/21 (42.9%)18/21 (85.7%)
Track 2: Nivolumab Plus BMS-813160 300 mg13/24 (54.2%)15/22 (68.2%)17/22 (77.3%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventTrack 1: Nivolumab Plus Ipilimumab (BMS-734016)Track 1: Nivolumab Plus Relatlimab (BMS-986016)Track 2: Nivolumab Plus Ipilimumab (BMS-734016)Track 2: Nivolumab Plus Relatlimab (BMS-986016)Track 2: Nivolumab Plus BMS-986205Track 2: Nivolumab Plus BMS-813160 150 mgTrack 2: Nivolumab Plus BMS-813160 300 mg
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/305/306/465/323/311/214/22
PneumoniaInfections and infestations4/300/300/463/322/310/212/22
HypercalcaemiaMetabolism and nutrition disorders2/303/302/460/321/310/210/22
Acute kidney injuryRenal and urinary disorders0/300/300/460/320/312/211/22
DyspnoeaRespiratory, thoracic and mediastinal disorders0/300/301/461/322/312/210/22
VomitingGastrointestinal disorders0/302/300/460/321/310/210/22
DehydrationMetabolism and nutrition disorders2/300/300/460/320/310/210/22
Spinal cord compressionNervous system disorders0/302/301/461/321/310/210/22
Wound dehiscenceInjury, poisoning and procedural complications0/300/300/461/322/310/210/22
Pleural effusionRespiratory, thoracic and mediastinal disorders1/300/300/461/322/310/210/22
Most frequent other events
Showing 10 of 104
Most frequent other events
EventTrack 1: Nivolumab Plus Ipilimumab (BMS-734016)Track 1: Nivolumab Plus Relatlimab (BMS-986016)Track 2: Nivolumab Plus Ipilimumab (BMS-734016)Track 2: Nivolumab Plus Relatlimab (BMS-986016)Track 2: Nivolumab Plus BMS-986205Track 2: Nivolumab Plus BMS-813160 150 mgTrack 2: Nivolumab Plus BMS-813160 300 mg
FatigueGeneral disorders9/3013/3015/4611/328/317/216/22
ConstipationGastrointestinal disorders3/308/305/4612/326/312/212/22
CoughRespiratory, thoracic and mediastinal disorders11/306/3010/468/326/316/212/22
NauseaGastrointestinal disorders10/307/3014/468/328/316/214/22
HeadacheNervous system disorders4/3010/305/461/322/313/213/22
PruritusSkin and subcutaneous tissue disorders10/306/3010/468/322/313/211/22
DiarrhoeaGastrointestinal disorders6/309/3014/467/325/316/211/22
AnaemiaBlood and lymphatic system disorders8/305/308/464/324/312/212/22
RashSkin and subcutaneous tissue disorders8/307/3012/467/323/314/212/22
Decreased appetiteMetabolism and nutrition disorders5/305/3012/468/324/315/213/22

Baseline characteristics

Arms 1 and 2 take into account both Track 1 and Track 2 participants as well as those rerandomized to the respective arms in Track 2.

Age, Categorical
Age, Categorical(Participants)Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mgTotal
<=18 years000000
Between 18 and 65 years4041161211120
>=65 years2515105762
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mgTotal
Female141664949
Male514020139133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mgTotal
Track 2 — Hispanic or Latino322108
Track 2 — Not Hispanic or Latino3734191210112
Track 2 — Unknown or Not Reported252054862
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: Nivolumab Plus Ipilimumab (BMS-734016)Arm 2: Nivolumab Plus Relatlimab (BMS-986016)Arm 3: Nivolumab Plus BMS-986205Arm 4: Nivolumab Plus BMS-813160 150 mgArm 5: Nivolumab Plus BMS-813160 300mgTotal
White6252231417168
Asian Indian100001
Chinese010001
Asian Other110002
Other122207
Black or African American001113
08

Study locations

32 sites
  • Local Institution - 0037
    New Haven, Connecticut 06520, United States
  • Local Institution
    Tampa, Florida 33612-9497, United States
  • Local Institution - 0031
    Augusta, Georgia 30912, United States
  • Local Institution - 0006
    Chicago, Illinois 60612, United States
  • Local Institution - 0007
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
  • Local Institution - 0011
    Detroit, Michigan 48201, United States
  • Local Institution - 0008
    Saint Louis, Missouri 63110, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Local Institution - 0005
    New York, New York 10065, United States
  • Local Institution - 0043
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0014
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Local Institution - 0002
    Allentown, Pennsylvania 18103, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Local Institution - 0025
    Nashville, Tennessee 37203, United States
  • Ut Southwestern Medical Center
    Dallas, Texas 75390-8570, United States
  • Local Institution - 0024
    Charlottesville, Virginia 22908, United States
  • University of Washington - Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Local Institution - 0032
    Westmead, New South Wales 2145, Australia
  • Monash Medical Centre Clayton
    Bentleigh, Victoria 3165, Australia
  • Local Institution - 0044
    Linz, Oberösterreich 4010, Austria
  • Local Institution - 0038
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0029
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0035
    Toronto, Ontario M5G 1Z6, Canada
  • Local Institution - 0034
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0030
    Québec, Quebec G1R 2J6, Canada
  • Local Institution
    Haifa, 3109601, Israel
  • Local Institution
    Ramat Gan, 52621, Israel
  • Local Institution - 0010
    Milano, 20133, Italy
  • Local Institution - 0012
    Napoli, 80131, Italy
09

References and documents

Publications

  • Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. PubMed 36328377 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Nov 2021, 57 months.

Results were first posted in Dec 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Dec 19, 2016
StartActual
Feb 2, 2017
Primary completionActual
Nov 23, 2021
CompletionActual
Nov 23, 2021
Results first posted
Dec 19, 2022
Last update
Dec 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02996110
Responsible party
Sponsor
First posted
Dec 19, 2016
Start date
Feb 2, 2017
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Results posted
Dec 19, 2022
Last update
Dec 19, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Linrodostat · BMS-813160

Start the discussion